New Search

If you are not happy with the results below please do another search

37 search results for: INNA-051

21

ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations

Melbourne, Australia, 15 June 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for two patent applications notably a composition-of-matter patent […]

23

ENA Respiratory Appoints Melissa Faris to Board

Melbourne, Australia, 23 April 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory infections, today announces the appointment of Melissa Faris as an independent Non-Executive Director. Melissa is Chief Business Officer of OMass Therapeutics, a leading UK-based private biotechnology company, and was previously […]

26

ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral

New US $3.13 million DOD contract extension to fund inclusion of younger adults in the ongoing Phase Ib study of INNA-051 nasal dry powder formulation and drug product optimization activities Melbourne, Australia, 5 September 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections […]

27

Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study

Post hoc analyses found a statistically significant reduction in the duration of flu infection and a dose-related trend toward a reduction in symptom duration. These results support the further clinical development of INNA-051 to mitigate the impact of natural infection by respiratory viruses such as SARS-CoV-2 and its variants: influenza, RSV, and the common cold, […]

28

Survey demonstrates that individuals with COPD seek more options to reduce risks of seasonal respiratory viral infections

ENA Respiratory and COPD Foundation survey confirms patients are overwhelmingly positive about taking an immune-modulating nasal spray to reduce lung disease exacerbations Survey was conducted through COPD360Net®, an innovative COPD Foundation program that identifies unmet patient needs and integrates the patient voice into therapy development Miami, Fla., and Melbourne, Australia, 30th January 2023 – A […]

29

ATS 2022 International Conference

ATS 2022 International Conference 13-18 May 2022 San Francisco, USA “Safety and Tolerability of the Toll-Like Receptor (TLR)2/6 Agonist INNA-051 in Healthy Adults” thematic poster session View poster

30

ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray

Sydney, Australia – ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and pandemic preparedness, has been selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), a component […]